Pharmacokinetic–pharmacodynamic modelling of acute N‐terminal pro B‐type natriuretic peptide after doxorubicin infusion in breast cancer

par Liang, Shuang, Brundage, Richard C., Jacobson, Pamala A., Blaes, Anne, Kirstein, Mark N.
Publié dans Br J Clin Pharmacol (2016)

Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients

par Takahashi, Takuto, Smith, Angela R., Jacobson, Pamala A., Fisher, James, Rubin, Nathan T., Kirstein, Mark N.
Publié dans Antimicrob Agents Chemother (2020)

Pharmacodynamic Modeling of Sequence-Dependent Antitumor Activity of Insulin-like Growth Factor Blockade and Gemcitabine

par Khatri, Amit, Brundage, Richard C., Hull, Jessica M., Williams, Brent W., Yee, Douglas, Kirstein, Mark N.
Publié 2011

Short communication: Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion

par Alharbi, Abeer F., Kratzke, Robert A., D’Cunha, Jonathan, Maddaus, Michael Anthony, Sanghavi, Kinjal, Kirstein, Mark N.
Publié dans Cancer Chemother Pharmacol (2018)

Cytotoxic purine nucleoside analogues bind to A(1), A(2A) and A(3) adenosine receptors

par Jensen, Kyle, Johnson, L’Aurelle A., Jacobson, Pamala A., Kachler, Sonja, Kirstein, Mark N., Lamba, Jatinder, Klotz, Karl-Norbert
Publié 2012

Randomized, Blinded Trial of Vitamin D(3) for Treating Aromatase Inhibitor-Associated Musculoskeletal Symptoms (AIMSS)

par Shapiro, Alice C., Adlis, Susan A., Robien, Kim, Kirstein, Mark N., Liang, Shuang, Richter, Sara A., Lerner, Rachel E.
Publié dans Breast Cancer Res Treat (2016)

A phase I dose finding study of intravenous voriconazole in pediatric patients undergoing hematopoietic cell transplantation

par Knight-Perry, Jessica, Jennissen, Cathryn, Long, Susie E., Hage, Stefanie, DeFor, Todd E., Chan, Wing T., Fisher, James, Kirstein, Mark N., Smith, Angela R.
Publié dans Bone Marrow Transplant (2019)

Personalized Fludarabine Dosing To Reduce Non-Relapse Mortality In Hematopoietic Stem Cell Transplant Recipients Receiving Reduced Intensity Conditioning

par Sanghavi, Kinjal, Wiseman, Anthony, Kirstein, Mark N., Cao, Qing, Brundage, Richard, Jensen, Kyle, Rogosheske, John, Kurtzweil, Andy, Long-Boyle, Janel, Wagner, John, Warlick, Erica D., Brunstein, Claudio G, Weisdorf, Daniel J., Jacobson, Pamala A.
Publié dans Transl Res (2016)

Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo

par Osum, Sara H, Coutts, Alexander W, Duerre, Dylan J, Tschida, Barbara R, Kirstein, Mark N, Fisher, James, Bell, W Robert, Delpuech, Oona, Smith, Paul D, Widemann, Brigitte C, Moertel, Christopher L, Largaespada, David A, Watson, Adrienne L
Publié dans Neurooncol Adv (2021)

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1

par Isakson, Sara H., Rizzardi, Anthony E., Coutts, Alexander W., Carlson, Daniel F., Kirstein, Mark N., Fisher, James, Vitte, Jeremie, Williams, Kyle B., Pluhar, G. Elizabeth, Dahiya, Sonika, Widemann, Brigitte C., Dombi, Eva, Rizvi, Tilat, Ratner, Nancy, Messiaen, Ludwine, Stemmer-Rachamimov, Anat O., Fahrenkrug, Scott C., Gutmann, David H., Giovannini, Marco, Moertel, Christopher L., Largaespada, David A., Watson, Adrienne L.
Publié dans Commun Biol (2018)